H1N1 vaccine licensure depends on adjuvant
This article was originally published in Pharmaceutical Approvals Monthly
Efforts are under way to expedite H1N1 flu vaccine development for a potential voluntary vaccination campaign in the fall. How FDA handles registration of the vaccine depends on whether an adjuvant is used - if it is manufactured using the same process as the seasonal flu vaccine, the vaccines will be licensed for use as a strain change, the same way FDA approves new strains of the seasonal vaccine. If an adjuvant is used, the products would be registered under an Emergency Use Authorization. FDA announced the licensure of the seasonal flu vaccine for the 2009-2010 flu season on July 20, and clarified that it will not protect against H1N1. The same five manufacturers that produce seasonal vaccine are working on the swine flu vaccine
You may also be interested in...
Results of a pivotal trial show BrainCool’s Cooral system is significantly more effective than the standard of care therapy in preventing oral mucositis in lymphoma patients.
Centaur-CytoTools introduces novel topical treatment for diabetic foot ulcers in India, for which they see limited direct competition and hope to change the way the difficult-to-treat diabetes complication is managed. Phase III studies are ongoing in Europe.
The head of the US Food and Drug Administration praised the life-saving work of device center staff in response to the coronavirus pandemic.